The future of psychiatry is precision
We develop biology-driven medicines for neuropsychiatric conditions so that patients can get better faster.
Measuring brain biology to drive clinical success
Our approach enables us to predict clinical response and identify patients who are most likely to benefit from our drug candidates.
Harnessing deep neurobiological insights to develop novel medicines
Built on 15 years of our field-leading neurobiology research, our clinical-stage drug candidates are designed to target core brain processes in people suffering from a range of neuropsychiatric conditions, with an initial focus on major depressive disorder, bipolar depression, and schizophrenia.
Driving innovation in psychiatry
We’re disrupting today’s trial-and-error approach to treating neuropsychiatric conditions. Our team leverages deep expertise in CNS drug development and commercialization to offer patients alternative treatment options for their conditions.